Psychedelics for Serious Illness and End of Life Care

Psychedelic Therapy for Serious Illness and End of Life Care

Webinar:  September 28, 2023, 4-6 pm.

Articles about psychedelic treatments for serious illness and end of life care seem to be everywhere. Rarely a week goes by without a newly published study appearing in a peer-reviewed medical journal, usually followed by reports of the study in prominent news outlets. In this webinar, we will present recent research on this topic, provide an update on the current legislation efforts to legalize these treatments in Washington State, and reflect on proposed treatment guidelines how legalization may impact treatment plans.

Panelists include:

Dr. David Gruenwald, Medical Director of the Palliative Care and Hospice Service at VA Puget Sound Health Care System

Lisa Yeager, MSW, LICSW, CPTR Licensed Independent Clinical Social Worker

Jesse Salomon, J.D. Democratic State Senator representing the 32nd Legislative District in Washington

Moderated by Devyani Chandran, Director, Palliative Care Institute, Western Washington University, Bellingham, Washington

This webinar has been approved for 2 CME credits.

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements of the Washington State Medical Association through the joint providership of PeaceHealth St. Joseph Medical Center and Western Washington University Palliative Care Institute. PeaceHealth St. Joseph is accredited by the WSMA to provide continuing medical education for physicians.

PeaceHealth St. Joseph designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 2 hour of Category I CME credits to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Disclosure:  No one in control of content for this educational activity has disclosed a relevant financial relationship with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing products used by or on patients.